Minocycline inhibits growth of epithelial ovarian cancer

Gynecologic Oncology

Volumn 125, Issue 2, 2012, Pages 433-440

  Pourgholami, Mohammad H ^a   Mekkawy, Ahmed H ^a   Badar, Samina ^a   Morris, David L ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Apoptosis; Cell cycle; Minocycline; Ovarian cancer; PARP; Tetracyclines

Indexed keywords

CASPASE 3; CYCLIN A; CYCLIN B; CYCLIN E; MINOCYCLINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL VIABILITY; COLONY FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA SYNTHESIS INHIBITION; DOWN REGULATION; DRUG SCREENING; EPITHELIAL OVARIAN CANCER; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUDE MOUSE; OVARY CANCER; PRIORITY JOURNAL;

ANIMALS; APOPTOSIS; CELL CYCLE; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CYCLINS; DNA, NEOPLASM; FEMALE; HUMANS; MICE; MICE, NUDE; MINOCYCLINE; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; SURVIVAL RATE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84859623859     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2012.01.006     Document Type: Article

References (44)

1. Morgan Jr RJ, Alvarez RD, Armstrong DK, Boston B, Chen LM, Copeland L, et al. Ovarian cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2008;6:766-94.
2. Sturgeon CM, Duffy MJ, Walker G. The National Institute for Health and Clinical Excellence (NICE) guidelines for early detection of ovarian cancer: the pivotal role of the clinical laboratory. Ann Clin Biochem 2011;48:295-9.
3. Blagden S, Gabra H. Promising molecular targets in ovarian cancer. Curr Opin Oncol 2009;21:412-9.
4. Guarneri V, Piacentini F, Barbieri E, Conte PF. Achievements and unmet needs in the management of advanced ovarian cancer. Gynecol Oncol 2010;117:152-8.
5. Bast Jr RC, Markman M. Chemotherapy: a new standard combination for recurrent ovarian cancer? Nat Rev Clin Oncol 2010;7:559-60.
6. Maffeis L, Veraldi S. Minocycline in the treatment of acne: latest findings. G Ital Dermatol Venereol 2010;145:425-9.
7. van Steenberghe D, Rosling B, Soder PO, Landry RG, van der Velden U, Timmerman MF, et al. A 15-month evaluation of the effects of repeated subgingival minocycline in chronic adult periodontitis. J Periodontol 1999;70:657-67. (Pubitemid 29284155)
8. Hu X, Zhou X, He B, Xu C, Wu L, Cui B, et al. Minocycline protects against myocardial ischemia and reperfusion injury by inhibiting high mobility group box 1 protein in rats. Eur J Pharmacol 2010;638:84-9.
9. Tao R, KimSH,Honbo N, Karliner JS, Alano CC.Minocycline protects cardiacmyocytes against simulated ischemia-reperfusion injury by inhibiting poly(ADP-ribose) polymerase-1. J Cardiovasc Pharmacol 2010;56:659-68.
10. Plane JM, Shen Y, Pleasure DE, Deng W. Prospects for minocycline neuroprotection. Arch Neurol 2010;67:1442-8.
11. Stirling DP, Koochesfahani KM, Steeves JD, Tetzlaff W. Minocycline as a neuroprotective agent. Neuroscientist 2005;11:308-22. (Pubitemid 41040860)
12. Kim HS, Suh YH. Minocycline and neurodegenerative diseases. Behav Brain Res 2009;196:168-79.
13. Zhu S, Stavrovskaya IG, Drozda M, Kim BY, Ona V, Li M, et al. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 2002;417:74-8. (Pubitemid 34498818)
14. van den Bogert C, Dontje BH, Kroon AM. The antitumour effect of doxycycline on a T-cell leukaemia in the rat. Leuk Res 1985;9:617-23. (Pubitemid 15059262)
15. van den Bogert C, Dontje BH, Holtrop M, Melis TE, Romijn JC, van Dongen JW, et al. Arrest of the proliferation of renal and prostate carcinomas of human origin by inhibition of mitochondrial protein synthesis. Cancer Res 1986;46:3283-9. (Pubitemid 16096857)
16. Selzer MG, Zhu B, Block NL, Lokeshwar BL. CMT-3, a chemically modified tetracycline, inhibits bony metastases and delays the development of paraplegia in a rat model of prostate cancer. Ann N Y Acad Sci 1999;878:678-82. (Pubitemid 29353646)
17. Shieh JM, Huang TF, Hung CF, Chou KH, Tsai YJ, Wu WB. Activation of c-Jun N-terminal kinase is essential for mitochondrialmembrane potential change and apoptosis induced by doxycycline inmelanoma cells. Br J Pharmacol 2010;160:1171-84.
18. Meng Q, Xu J, Goldberg ID, Rosen EM, Greenwald RA, Fan S. Influence of chemically modified tetracyclines on proliferation, invasion and migration properties of MDA-MB-468 human breast cancer cells. Clin Exp Metastasis 2000;18:139-46. (Pubitemid 32165247)
19. Dhanesuan N, Sharp JA, Blick T, Price JT, Thompson EW. Doxycycline-inducible expression of SPARC/Osteonectin/BM40 in MDA-MB-231 human breast cancer cells results in growth inhibition. Breast Cancer Res Treat 2002;75:73-85.
20. Cartwright AC, Hatfield HL, Yeadon A, London E. A comparison of the bioavailability of minocycline capsules and film-coated tablets. J Antimicrob Chemother 1975;1:317-22.
21. Smith C,Woods CG,Woods MJ. Absorption ofminocycline. J Antimicrob Chemother 1984;13:93.
22. Carney S, Butcher RA, Dawborn JK, Pattison G. Minocycline excretion and distribution in relation to renal function in man. Clin Exp Pharmacol Physiol 1974;1:299-308.
23. Macdonald H, Kelly RG, Allen ES, Noble JF, Kanegis LA. Pharmacokinetic studies on minocycline in man. Clin Pharmacol Ther 1973;14:852-61.
24. Pourgholami MH, Cai ZY, Badar S, Wangoo K, Poruchynsky MS, Morris DL. Potent inhibition of tumoral hypoxia-inducible factor 1alpha by albendazole. BMC Cancer 2010;10:143.
25. Pourgholami MH, Wangoo KT, Morris DL. Albendazole-cyclodextrin complex: enhanced cytotoxicity in ovarian cancer cells. Anticancer Res 2008;28:2775-9.
26. Pourgholami MH, Woon L, Almajd R, Akhter J, Bowery P, Morris DL. In vitro and in vivo suppression of growth of hepatocellular carcinoma cells by albendazole. Cancer Lett 2001;165:43-9. (Pubitemid 32206656)
27. Metz R, Duhadaway JB, Rust S, Munn DH, Muller AJ, Mautino M, et al. Zinc protoporphyrin IX stimulates tumor immunity by disrupting the immunosuppressive enzyme indoleamine 2,3-dioxygenase. Mol Cancer Ther 2010;9:1864-71.
28. D'Amours D, Sallmann FR, DixitVM, Poirier GG. Gain-of-function of poly(ADP-ribose) polymerase-1 upon cleavage by apoptotic proteases: implications for apoptosis. J Cell Sci 2001;114:3771-8. (Pubitemid 33041059)
29. Tewari M, Quan LT, O'Rourke K, Desnoyers S, Zeng Z, Beidler DR, et al. Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell 1995;81:801-9.
30. Matsuki S, Iuchi Y, Ikeda Y, Sasagawa I, Tomita Y, Fujii J. Suppression of cytochrome c release and apoptosis in testes with heat stress by minocycline. Biochem Biophys Res Commun 2003;312:843-9. (Pubitemid 37468248)
31. Dumont EA, Lutgens SP, Reutelingsperger CP, Bos GM, Hofstra L. Minocycline inhibits apoptotic cell death in a murine model of partial flap loss. J Reconstr Microsurg 2010;26:523-8.
32. Cotmore SF, Tattersall P. Alternate splicing in a parvoviral nonstructural gene links a common amino-terminal sequence to downstream domains which confer radically different localization and turnover characteristics. Virology 1990;177: 477-87. (Pubitemid 20235168)
33. Wang J, Wei Q, Wang CY, Hill WD, Hess DC, Dong Z. Minocycline up-regulates Bcl-2 and protects against cell death in mitochondria. J Biol Chem 2004;279:19948-54. (Pubitemid 38623437)
34. Xia D, Shen K, Zhong W, Pan H. Administration of minocycline ameliorates damage in a renal ischemia/reperfusion injury model. Clin Invest Med 2011;34:E55-63.
35. Teng YD, Choi H, Onario RC, Zhu S, Desilets FC, Lan S, et al. Minocycline inhibits contusion-triggered mitochondrial cytochrome c release and mitigates functional deficits after spinal cord injury. Proc Natl Acad Sci U S A 2004;101:3071-6. (Pubitemid 38327736)
36. Kupsch K, Hertel S, Kreutzmann P, Wolf G, Wallesch CW, Siemen D, et al. Impairment of mitochondrial function by minocycline. FEBS J 2009;276:1729-38.
37. Wei X, Zhao L, Liu J, Dodel RC, Farlow MR, Du Y. Minocycline prevents gentamicininduced ototoxicity by inhibiting p38 MAP kinase phosphorylation and caspase 3 activation. Neuroscience 2005;131:513-21. (Pubitemid 40222458)
38. Song Y, Wei EQ, Zhang WP, Ge QF, Liu JR, Wang ML, et al. Minocycline protects PC12 cells against NMDA-induced injury via inhibiting 5-lipoxygenase activation. Brain Res 2006;1085:57-67. (Pubitemid 43728193)
39. Alano CC, Kauppinen TM, Valls AV, Swanson RA. Minocycline inhibits poly(ADPribose) polymerase-1 at nanomolar concentrations. Proc Natl Acad Sci U S A 2006;103:9685-90. (Pubitemid 43955885)
40. Dhib-Jalbut S, Arnold DL, Cleveland DW, Fisher M, Friedlander RM, Mouradian MM, et al. Neurodegeneration and neuroprotection in multiple sclerosis and other neurodegenerative diseases. J Neuroimmunol 2006;176:198-215. (Pubitemid 44080333)
41. Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer.Nature 2001;411: 342-8. (Pubitemid 32467043)
42. Benitz KF, Roberts GK, Yusa A. Morphologic effects of minocycline in laboratory animals. Toxicol Appl Pharmacol 1967;11:150-70.
43. Hill GB. Therapeutic evaluation of minocycline and tetracycline for mixed anaerobic infection in mice. Antimicrob Agents Chemother 1977;11:625-30. (Pubitemid 8093319)
44. Bapat SA, Krishnan A, Ghanate AD, Kusumbe AP, Kalra RS. Gene expression: protein interaction systems network modeling identifies transformation- associated molecules and pathways in ovarian cancer. Cancer Res 2010;70:4809-19.